Research
PsiloThera launches quantum technology drug development programme
The company aims to deploy its quantum technology programme in order to shorten drug development time.

Published
10 months agoon

A quantum drug development programme has been launched by psychedelic healthcare company PsiloThera.
PsiloThera, a psychedelic healthcare innovation and life sciences company developing psilocybin-based drugs and therapies, has announced the launch of its Quantum Technology Drug Development Programme – a technology that could help solve a number of problems in both drug discovery and drug development.
The company’s focus is on the treatment of indications such as depression, anxiety, post-traumatic stress disorder (PTSD), eating disorders and addictions, as well as cognitive diseases and neurological disorders such as Alzheimer’s disease, dementia and autism.
Innovation in drug development
The company’s specialised treatment programmes will provide care for veterans, first responders and patients with treatment-resistant mental illnesses. The company aims to deploy its quantum technology programme in order to shorten drug development time.
PsiloThera CEO, John Atanasio said: “PsiloThera is among the first companies focused on developing novel therapeutics by deploying quantum technology that can collect and send materials through organic devices. PsiloThera’s strategy is to have its products lead the future of energy-based nutrients and medication delivery systems.
“Quantum technology may lead to advances that could ultimately change the way that humans digest supplements, medications and nutrients. Our Quantum Technology Advisors projects that the technology projects to deliver significant improvements in areas of pharmaceutical dispensing issues and adverse effects.
“Quantum Technology may lead to significant reductions in drug development time and costs, giving PsiloThera a possible major competitive advantage if that were to prove true.”
The Journal of American Medical Association reported in a 2020 study that treatment of psilocybin works better than usual anti-depressant medications. PsiloThera’s vertical business model includes fungi cultivation, Research & Development, drug development, a telehealth platform and PsiloThera Treatment Centres.
You may like
Psychedelics for addiction research gets $2.7m grant
Patient approved to receive psilocybin therapy for MDD
New partnership to harness digital tools to enhance psychedelic care
DEA grants approval for the manufacture of psychedelic compounds
Numinus receives Health Canada SAP approval for psilocybin therapy
Clerkenwell Health is launching a free UK psychedelic therapist training programme
Research
Psychedelics for addiction research gets $2.7m grant
The grant will fund research to investigate the efficacy of psychedelics for treating a variety of addiction disorders.

Published
24 hours agoon
25th May 2022
The University of California, Davis (UC Davis) and the University of Colorado Anschutz Medical Campus have received a $2.7m (~£2.15m) grant from the National Institute on Drug Abuse, part of the National Institutes of Health, to research psychedelics.
The researchers will use the funding to screen hundreds of compounds to discover new, non-hallucinogenic treatments for substance use disorders.
With previous research having shown that psychedelic drugs can rewire parts of the brain involved in depression, substance abuse and post-traumatic stress disorder, David Olson, associate professor in the departments of Chemistry, and Biochemistry and Molecular Medicine at UC Davis, is searching for similar effects among compounds without the hallucinogenic effects of drugs like LSD.
He calls these compounds psychoplastogens, for their ability to modify the brain.
Olson commented: “I’m very excited that NIDA is recognising the potential that psychoplastogens might have for patients with substance use disorders.
“This grant will help us to understand the basic mechanisms by which these compounds impact addiction, and hopefully develop more effective and better-tolerated treatments.”
Olson’s work is part of a growing focus on psychedelics research at UC Davis and UC Davis Health. His lab has synthesised hundreds of molecules related to psychedelics in the search for new drug therapies.
One such molecule, tabernanthalog, or TBG, produces both rapid and sustained anti-addictive effects in rodent models of heroin and alcohol self-administration.
The research will include mechanistic studies to understand how TBG impacts addiction and the development of new compounds with psychoplastogenic effects, he said. The team will use high-throughput screening to test for efficacy, safety and treatment potential. Promising compounds will undergo additional animal testing at CU Anschutz.
Delix Therapeutics, a startup founded by Olson, is also investigating non-hallucinogenic psychoplastogens for treating depression, anxiety and related disorders but is not involved in the project.
Research
World’s first study on ketamine for behavioural addiction now complete
Awakn Life Sciences will now carry out a larger study following positive results.

Published
6 days agoon
20th May 2022
Awakn Life Science’s study exploring the use of ketamine as a treatment for Gambling Disorder, Internet Gaming Disorder, Binge Eating Disorder and Compulsive Sexual Behavior is now complete.
Ketamine may provide a new treatment solution for behavioural addictions, according to the study researchers.
Gambling Disorder, Internet Gaming Disorder and Binge Eating Disorder affect up to 450 million, 235 million and 100 million people across the globe respectively. Compulsive Sexual Behavior affects up to 350 million people.
Awakn, which highlights that the current standard of care for these conditions is poor, investigated ketamine as a new treatment approach for behavioural addictions by opening a window in which the brain can make new connections to change behaviour.
The findings indicated the desired effects via potentially novel mechanisms – results that merit a larger study and further exploration, which Awakn is now initiating.
The study was led by Professor Celia Morgan, Awakn’s head of ketamine-assisted therapy, Professor of psychopharmacology at the University of Exeter, and an internationally respected expert in the therapeutic use of ketamine.
Morgan commented: “These promising early findings may suggest a new treatment solution in behavioural addictions, which are growing rapidly across the globe, and as yet, are a completely unmet treatment need.
“The team are excited to be starting these new significant studies which promise to bring considerable innovation to the field.”
According to Awakn, the study also supports its Intellectual Property (IP) strategy and existing filed patent applications.
Awakn CEO, Anthony Tennyson commented: “This study is hugely encouraging and gave us all the data we could have hoped for. Critically, it also showed us that a larger study is merited, and we will now pursue this.
“For such a huge cohort of over a billion people to be suffering with no pharmacological treatment available to them, is unacceptable and we will strive to deliver therapies to patients who are in desperate need.”
Research
New partnership to harness digital tools to enhance psychedelic care
Beckley Psytech is entering into a partnership with Empatica to carry out one of the world’s first trials with psychedelics and digital tools.

Published
7 days agoon
19th May 2022
Beckley Psytech and Empatica are collaborating to support the collection and analysis of data in Beckley Psytech’s future clinical trials.
The partnership will capture behavioural and physiological signals and predictive biomarkers in Beckley Psytech’s upcoming Phase 2 clinical trials. To do this, Beckley Psytech will harness Empatica’s medical-grade EmbracePlus wearable and software.
The trials will be evaluating the use of 5-MeO-DMT in combination with psychotherapy in the treatment of treatment resistant depression (TRD).
Empatica, Inc., specialises in medical wearables and digital biomarkers, offering continuous, passive and unobtrusive monitoring for patients with neurological conditions. Beckley has stated the partnership is the latest step in its digital strategy to develop personalised treatment programmes for patients in need.
The digital enhancement of the psychedelic treatment pathway aims to support patients before, during and after treatment through the application of novel, predictive biomarkers which will potentially identify early signals of patient response and relapse.
CEO of Beckley Psytech, Cosmo Feilding Mellen, said: “As we look to enhance the safety and effectiveness of our psychedelic treatments with patient-centric digital tools, this partnership with Empatica accelerates our strategy of creating an integrated treatment model to ensure patients are fully supported through the treatment journey.
“We are thrilled to be working with Empatica, a pioneering digital health company, through our upcoming clinical trials and look forward to further evolving our understanding of how digital tools can support and potentially improve outcomes for patients with neurological and psychiatric conditions.”
Beckley Psytech aims to establish a complete, end-to-end personalised psychedelic treatment programme, combining advanced digital phenotyping capabilities, such as those developed by Empatica, with psychedelic-assisted psychotherapy.
The company has stated that this approach will allow clinicians to provide patients with continuous access to personalised therapy support beyond their treatment, delivering potentially improved outcomes and safety for patients and healthcare systems.
Matteo Lai, CEO of Empatica, commented: “We couldn’t be more excited to collaborate with Beckley Psytech on this important project, especially since over the past two years, we have witnessed how critical mental health and depression have become globally.
“The potential of psychedelic treatments in the field can help millions of patients, and Empatica is honoured to contribute its technology in one of the world’s first trials with psychedelics and digital tools, to advance these novel therapies with targeted help and better engagement.”
Recent Articles
- Top UK and European academics join Clerkenwell Health advisory board
- Psychedelics for addiction research gets $2.7m grant
- Beckley Psytech strengthens leadership team as it progresses clinical pipeline
- Patient approved to receive psilocybin therapy for MDD
- World’s first study on ketamine for behavioural addiction now complete
- New partnership to harness digital tools to enhance psychedelic care
Trending
- World’s first study on ketamine for behavioural addiction now complete
- New partnership to harness digital tools to enhance psychedelic care
- DEA grants approval for the manufacture of psychedelic compounds
- Numinus receives Health Canada SAP approval for psilocybin therapy
- Clerkenwell Health is launching a free UK psychedelic therapist training programme
Trending
- News8 months ago
Could Italy decriminalise psychotropic substance cultivation?
- Insight6 months ago
Microdosing: separating fact from fiction
- Events8 months ago
Wonderland: Miami to host world’s largest psychedelic conference
- News10 months ago
Awakn’s second psychedelic therapy clinic to open in London
- News10 months ago
Heroic Hearts to research psilocybin treatment for brain injury in veterans
- Medicinal5 months ago
Ketamine-assisted therapy for alcohol addiction could save lives
- Policy5 months ago
Global coalition launches to push for psilocybin rescheduling
- News5 months ago
Developing a gold standard for psychedelic care